Literature DB >> 10586042

MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants.

C P Simmons1, P Mastroeni, R Fowler, M Ghaem-maghami, N Lycke, M Pizza, R Rappuoli, G Dougan.   

Abstract

The ability of enterotoxin-based mucosal adjuvants to induce CD8+ MHC class I-restricted CTL responses to a codelivered bystander Ag was examined. Escherichia coli heat-labile toxin (LT), or derivatives of LT carrying mutations in the A subunit (LTR72, LTK63), were tested in parallel with cholera toxin (CT) or a fusion protein consisting of the A1 subunit of CT fused to the Ig binding domain of Staphylococcus aureus protein A (called CTA1-DD). Intranasal (i.n.) immunization of C57BL/6 mice with CT, CTA1-DD, LT, LTR72, LTK63, but not rLT-B, elicited MHC class I-restricted CD8+ T cell responses to coadministered OVA or the OVA CTL peptide SIINFEKL (OVA257-264). CT, LT, and LTR72 also induced CTL responses to OVA after s.c. or oral coimmunization whereas LTK63 only activated responses after s.c. coimmunization. rLT-B was unable to adjuvant CTL responses to OVA or OVA257-264 administered by any route. Mice treated with an anti-CD4 mAb to deplete CD4+ T cells mounted significant OVA-specific CTL responses after i.n. coadministration of LT with OVA or OVA257-264. Both 51Cr release assays and IFN-gamma enzyme-linked immunospot assays indicated that IFN-gamma-/- and IL-12 p40-/- gene knockout mice developed CTL responses equivalent to those detected in normal C57BL/6 mice. The results highlight the versatility of toxin-based adjuvants and suggest that LT potentiates CTL responses independently of IL-12 and IFN-gamma and probably by a mechanism unrelated to cross-priming.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10586042

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus.

Authors:  Sang-Moo Kang; Richard W Compans
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 2.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

Review 3.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

4.  Immunological activation following transcutaneous delivery of HR-gp100 protein.

Authors:  Shoshana Frankenburg; Igor Grinberg; Ziva Bazak; Lena Fingerut; Jacob Pitcovski; Raphael Gorodetsky; Tamar Peretz; Ram M Spira; Yehuda Skornik; Ronald S Goldstein
Journal:  Vaccine       Date:  2007-04-25       Impact factor: 3.641

5.  M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

Authors:  D G Eliasson; A Omokanye; K Schön; U A Wenzel; V Bernasconi; M Bemark; A Kolpe; K El Bakkouri; T Ysenbaert; L Deng; W Fiers; X Saelens; N Lycke
Journal:  Mucosal Immunol       Date:  2017-03-01       Impact factor: 7.313

6.  Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses.

Authors:  D Chen; K F Weis; Q Chu; C Erickson; R Endres; C R Lively; J Osorio; L G Payne
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.

Authors:  Pallavi R Manuri; Bharti Nehete; Pramod N Nehete; Rose Reisenauer; Seth Wardell; Amy N Courtney; Ratish Gambhira; Dakshyani Lomada; Ashok K Chopra; K Jagannadha Sastry
Journal:  Vaccine       Date:  2007-01-24       Impact factor: 3.641

8.  Characterization and development of T-Cell immune responses in B-cell-deficient (Igh-6(-/-)) mice with Salmonella enterica serovar Typhimurium infection.

Authors:  Sanja Ugrinovic; Nathalie Ménager; Natalie Goh; Pietro Mastroeni
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

9.  Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens.

Authors:  Amy N Courtney; Pramod N Nehete; Bharti P Nehete; Prakash Thapa; Dapeng Zhou; K Jagannadha Sastry
Journal:  Vaccine       Date:  2009-02-05       Impact factor: 3.641

10.  Functional diversity of heat-labile toxins (LT) produced by enterotoxigenic Escherichia coli: differential enzymatic and immunological activities of LT1 (hLT) AND LT4 (pLT).

Authors:  Juliana F Rodrigues; Camila Mathias-Santos; Maria Elisabete Sbrogio-Almeida; Jaime H Amorim; Joaquim Cabrera-Crespo; Andrea Balan; Luís C S Ferreira
Journal:  J Biol Chem       Date:  2010-12-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.